Skip to main content

Home/ OARS funding Biomed/ Group items tagged neuroscience

Rss Feed Group items tagged

MiamiOH OARS

DoD Hearing Restoration Translational Research Award - 0 views

  •  
    It is estimated that more than 30 million Americans over the age of 12 years have hearing loss in both ears and an estimated 48 million have hearing loss in at least one ear. The most recent data from the Department of Veterans Affairs (VA) indicates that there are 1.1 million Veterans with Service-connected disability due to hearing loss. The HRRP will fund innovative research that has the potential to maximize operational performance, medical readiness, and quality of life for Service members, Veterans, and others living with significant auditory system injuries.
MiamiOH OARS

PAR-18-761: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurot... - 0 views

  •  
    This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.
MiamiOH OARS

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Va... - 0 views

  •  
    This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.
MiamiOH OARS

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic A... - 0 views

  •  
    This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.
MiamiOH OARS

Request for Applications | The Chan Zuckerberg Initiative - 0 views

  •  
    The Chan Zuckerberg Initiative is inviting applications to join the CZI Neurodegeneration Challenge Network. The goal of this interdisciplinary collaborative initiative is to bring together forward-thinking scientists to work on the challenge of neurodegenerative disorders, with a focus on basic mechanisms in the context of human disease biology.
MiamiOH OARS

RFA-NS-18-019: BRAIN Initiative: Optimization of Transformative Technologies for Large ... - 0 views

  •  
    Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. Although invention and proof-of-concept testing of new technologies are a key component of the BRAIN Initiative, to achieve their potential these technologies must also be optimized through feedback from end-users in the context of the intended experimental use. This FOA seeks applications for the optimization of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and temporal scales, in any region and throughout the entire depth of the brain. This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of-concept testing, and are appropriate for accelerated development of hardware and software while scaling manufacturing techniques towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience practice.
    Proposed technologies should be compatible with experiments in behaving animals, and should include advancements that enable or reduce major barriers to hypothesis-driven experiments. Technologies may engage diverse types of signaling beyond neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. Applications are expected to integrate appropriate domains of expertise, including where appropriate biological, chemical and physical sciences, engineering, computational modeling and statistical analysis. Also listed under R01
MiamiOH OARS

PAR-18-711: Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clin... - 0 views

  •  
    This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.
    This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator should apply to the companion FOA (PAR-18-710).
MiamiOH OARS

Program to Accelerate Clinical Trials | Alzheimer's Drug Discovery Foundation - 0 views

  •  
    Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies.
    The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects.
    Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.
MiamiOH OARS

PAR-18-664: Clinical Validation of Candidate Biomarkers for Neurological Diseases (U01 ... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond).
MiamiOH OARS

PAR-18-661: Pathway and Target Identification for Alzhiemers Disease Related Dementias ... - 0 views

  •  
    The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology.
MiamiOH OARS

Clinical Validation of Candidate Biomarkers for Neurological Diseases (U01 Clinical Tr - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of neurological disease for use in multi-site clinical trials and clinical practice.
MiamiOH OARS

Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed) - 0 views

  •  

    This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.
MiamiOH OARS

Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (U0... - 0 views

  •  
    The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.
MiamiOH OARS

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and... - 0 views

  •  
    This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will collaborate and conduct the trial within the NIH StrokeNet. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure.
MiamiOH OARS

PAR-18-543: CREATE Bio Development Track: Preclinical and Early-Phase Clinical Developm... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
MiamiOH OARS

PAR-18-515: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools ... - 0 views

  •  
    The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.
MiamiOH OARS

RFA-NS-18-018: BRAIN Initiative: Biology and Biophysics of Neural Stimulation (R01 - Cl... - 0 views

  •  
    The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat and prevent brain disorders.

MiamiOH OARS

RFA-AG-18-029: Interdisciplinary Research to Understand the Complex Biology of Resilien... - 0 views

  •  
    To date, the pursuit of disease-modifying therapy development for Alzheimer's disease (AD) has been primarily informed by the study of diseased individuals, often by comparing genomic and other molecular, cellular and physiologic features in AD cases and controls. This has proven extremely challenging given the disease's heterogeneity and its multifactorial etiology. There is a growing appreciation that the development of effective treatment and prevention for complex diseases such as AD can benefit from gaining a much deeper understanding of what it means to be well and which genomic, epigenomic, environmental, social, and behavioral factors promote wellness and protection against disease.

MiamiOH OARS

RFA-EY-17-003: NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate ... - 0 views

  •  

    The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders.

    This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement therapy. Model systems using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA.
MiamiOH OARS

CURE Epilepsy - 0 views

  •  
    The Taking Flight Award seeks to promote the careers of young epilepsy investigators, enabling them to develop a research focus independent of their mentor(s).
    In 2018, CURE will issue one request for proposals for the Taking Flight Award. Please refer to the LOI guidelines for an overview of CURE's 2018 priority areas, application instructions and FAQs.
    Eligibility
    You must fall into one of the following categories to be eligible for the Taking Flight Award:
    A senior postdoctoral fellow who has a minimum of 3 years postdoctoral experience
    A clinical fellow who is a Neurology Resident in his/her Neurology training and considering Epilepsy Fellowships
    Newly appointed faculty within one year of having completed postdoctoral training
1 - 20 of 235 Next › Last »
Showing 20 items per page